For more than 15 years NICE has punched above its weight internationally but as it comes under attack for its methodology, will its international clout suffer? - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2016/june_2016/nice_heavyweight_champion_of_the_worldBrexit was supposed to be an opportunity for the UK to strike trade deals outside the EU, but the going is tough - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2019/julyaugust_2019/the_promised_landThe pharma industry has been pivotal during the pandemic and this focus looks set to continue into 2022 - Magazine Article - PharmaTimes
by Ana Nicholls is Industry Director at EIU
https://www.pharmatimes.com/magazine/2021/december_2021/pharmaceuticals_in_2022The proposed industrial strategy for the life sciences sector sets out some ambitious objectives – probably too ambitious, says Ana Nicholls - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2017/october_2017/new_life_for_life_sciencesThe prospect of Brexit-related drugs shortages is looming, although a snarl-up may yet be avoided - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2019/april/a_state_of_confusionAna Nicholls asks whether GSK’s revenue drop is a short-term blip or a sign of bigger problems - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2018/june_2018/is_trouble_on_the_horizon_for_gskHow the recent UK election could affect the NHS - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2017/pharmatimes_julyaugust_2017/keeping_the_promisesThe industry needs to tread carefully in the future – but there could be upsides to having less red tape and softer tax policies - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2016/december/trump_and_brexit_good_news_for_pharmaOff-label use of medicines has always been a vexed issue. In theory, treatments should only be used as indicated, where their safety and efficacy has been proven. Indeed, several pharma companies have received large fines for suggesting otherwise in
by Ana Nicholls, Economist Intelligence Unit
https://www.pharmatimes.com/news/smartviews_off-label_but_under_debate_971338Ana Nicholl's outlook on what this year might have in store for the sector - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2021/januaryfebruary_2021/expectations_for_healthcare_in_2021
